Search research articles
Contact Us
Filters
Showing results (901-910 of 1,038) with videos related to
Page
of 104
Sort By:
British Journal of Haematology
|
April 12, 2017
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib
Jeffrey A Jones, Peter Hillmen, Steven Coutre, et al.
Pediatrics
|
October 2, 2019
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Mark L Wolraich, Joseph F Hagan, Carla Allan, et al.
The New England Journal of Medicine
|
November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemias
Jorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
Blood
|
January 2, 2014
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia
John C Byrd, John M Pagel, Farrukh T Awan, et al.
Blood
|
March 5, 2014
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Ian W Flinn, Richard van der Jagt, Brad S Kahl, et al.
Blood Advances
|
October 17, 2024
Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network
Minoo Battiwalla, Michael Tees, Ian Flinn, et al.
Cephalalgia : an International Journal of Headache
|
February 24, 2025
Combined effects of cannabidiol and Δ9-tetrahydrocannabinol alleviate migraine-like symptoms in mice
Erik Zorrilla, Georgii Krivoshein, Adisa Kuburas, et al.
British Journal of Haematology
|
February 12, 2019
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia
William G Wierda, John C Byrd, Susan O'Brien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 7, 2023
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
John N Allan, Ian W Flinn, Tanya Siddiqi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2017
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Steven E Coutré, Richard R Furman, Ian W Flinn, et al.
Page
of 104
Search research articles
Search
Showing results (901-910 of 1,038) with videos related to
Sort By:
Page
of 104
British Journal of Haematology
|
April 12, 2017
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib
Jeffrey A Jones, Peter Hillmen, Steven Coutre, et al.
Pediatrics
|
October 2, 2019
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Mark L Wolraich, Joseph F Hagan, Carla Allan, et al.
The New England Journal of Medicine
|
November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemias
Jorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
Blood
|
January 2, 2014
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia
John C Byrd, John M Pagel, Farrukh T Awan, et al.
Blood
|
March 5, 2014
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Ian W Flinn, Richard van der Jagt, Brad S Kahl, et al.
Blood Advances
|
October 17, 2024
Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network
Minoo Battiwalla, Michael Tees, Ian Flinn, et al.
Cephalalgia : an International Journal of Headache
|
February 24, 2025
Combined effects of cannabidiol and Δ9-tetrahydrocannabinol alleviate migraine-like symptoms in mice
Erik Zorrilla, Georgii Krivoshein, Adisa Kuburas, et al.
British Journal of Haematology
|
February 12, 2019
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia
William G Wierda, John C Byrd, Susan O'Brien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 7, 2023
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
John N Allan, Ian W Flinn, Tanya Siddiqi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2017
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Steven E Coutré, Richard R Furman, Ian W Flinn, et al.
Page
of 104